Sign in

Research summary ·

Antibiotic Exposure and Treatment Outcomes in Head and Neck Squamous Cell Carcinoma and Nasopharyngeal Carcinoma: A Systematic Review and Meta-Analysis.

Written based on 1 research study on PubMed, searched on 11 Nov 2026.

What was studied

This review asked if antibiotic use around the start of cancer treatment relates to outcomes. People had head and neck squamous cell carcinoma or nasopharyngeal carcinoma. They got immune checkpoint inhibitors, chemoradiotherapy or both. The team searched PubMed, Embase and Scopus from January 2015 to March 2026. 6,293 patients were included. 4,507 of them were in survival analyses.

What they found

Antibiotic exposure was linked to worse overall survival, with a hazard ratio of 1.78. It was linked to worse progression-free survival, with a hazard ratio of 1.58. The links held in the checkpoint inhibitor group and in the chemoradiotherapy group. Antibiotics given before or during treatment both went with worse survival. The response rate was lower in exposed patients. Most studies had serious or high risk of bias.

What it means for patients

The authors say antibiotic exposure around treatment start was linked to worse survival and response. They say the evidence is mostly observational, with strong confounding. They say cause cannot be inferred. They say prospective microbiome studies are needed.

Why it is not certain yet

Most studies had serious or high risk of bias. This came mainly from confounding by indication. The evidence is mostly observational. The link does not show that antibiotics cause worse outcomes. It cannot show cause.

Source

Antibiotic Exposure and Treatment Outcomes in Head and Neck Squamous Cell Carcinoma and Nasopharyngeal Carcinoma: A Systematic Review and Meta-Analysis.

PubMed · PMID 42998127

We restate facts from the source record in our own words. The original wording belongs to its publisher.

This page is not medical advice. Talk to your doctor about your own care.

Back to Head and neck cancer publications